CITATION REPORT List of articles citing

A VEGFR1 antagonistic peptide inhibits tumor growth and metastasis through VEGFR1-PI3K-AKT signaling pathway inhibition

DOI: 99.0000/PMC4656737 American Journal of Cancer Research, 2015, 5, 3149-61.

Source: https://exaly.com/paper-pdf/122595764/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1 la the PI3K/AKT/mTOR pathway. <i>Oncotarget</i> , 2016 , 7, 20193-208	3.3	82
20	Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 74	12.8	32
19	I-F56 Peptide as Radioanalysis Agent Targeting VEGFR1 in Mice Xenografted with Human Gastric Tumor. <i>ACS Medicinal Chemistry Letters</i> , 2017 , 8, 266-269	4.3	6
18	Vascular endothelial growth receptor 1 acts as a stress-associated protein in the therapeutic response to thalidomide. <i>Experimental and Therapeutic Medicine</i> , 2017 , 14, 4263-4271	2.1	
17	The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	5
16	A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis. <i>Scientific Reports</i> , 2018 , 8, 17924	4.9	25
15	Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased anti-tumor efficacy. <i>Theranostics</i> , 2018 , 8, 2094-2106	12.1	17
14	Identification of genes underlying phenotypic plasticity of wing size via insulin signaling pathway by network-based analysis in Sogatella furcifera. <i>BMC Genomics</i> , 2019 , 20, 396	4.5	4
13	Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	29
12	Synergistic Anti-Angiogenic Effects Using Peptide-Based Combinatorial Delivery of siRNAs Targeting VEGFA, VEGFR1, and Endoglin Genes. <i>Pharmaceutics</i> , 2019 , 11,	6.4	6
11	The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 783-792	3.5	O
10	Correlation among gene promoter methylation, protein overexpression, and clinical pathology in early gastric cancer <i>Translational Cancer Research</i> , 2020 , 9, 3499-3506	0.3	
9	Indole hydrazide compound ZJQ-24 inhibits angiogenesis and induces apoptosis cell death through abrogation of AKT/mTOR pathway in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2020 , 11, 926	9.8	5
8	lncRNA PVT1 Promotes Tumorigenesis of Colorectal Cancer by Stabilizing miR-16-5p and Interacting with the VEGFA/VEGFR1/AKT Axis. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 20, 438-450	10.7	36
7	Inhibitory Effects of Hayata Extract ECB on Melanoma-Induced Hyperplasia of Blood Vessels in Zebrafish Embryos. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021 , 2021, 5543259	2.3	O
6	AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 650963	5.3	3
5	Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. <i>Oncotarget</i> , 2016 , 7, 72868-72885	3.3	19

CITATION REPORT

4	"III Cell-IL17A-Neutrophil" Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy. <i>Frontiers in Immunology</i> , 2021 , 12, 699478	8.4	1
3	BRAF kinase inhibitor exerts anti-tumor activity against breast cancer cells via inhibition of FGFR2. <i>American Journal of Cancer Research</i> , 2016 , 6, 1040-52	4.4	1
2	MiR-122 targets VEGFC in bladder cancer to inhibit tumor growth and angiogenesis. <i>American Journal of Translational Research (discontinued)</i> , 2016 , 8, 3056-66	3	34
1	Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity <i>Journal of Nanobiotechnology</i> , 2022 , 20, 7	9.4	Ο